MTHFR variation, folate activation and the case for methylfolate

MTHFR · rs1801133 (C677T), rs1801131 (A1298C) · 10 references · Version 1.0 · MyGNLab

The MTHFR enzyme performs the final step that turns dietary and supplemental folate into 5-methyltetrahydrofolate, the form the body can use. Two common variants slow that step, and carrying two copies of rs1801133 leaves roughly a third of normal enzyme activity. Across meta-analyses and controlled trials, reduced-activity genotypes show lower blood folate, higher homocysteine and a different response to the same folic acid dose. Supplying folate already in its active form bypasses the weakened step, which is the mechanistic basis for using methylfolate rather than folic acid where the genotype calls for it.

What MTHFR does

Folate arrives from food and supplements in forms your cells can't use directly. One enzyme, methylenetetrahydrofolate reductase, performs the final step that turns it into 5-methyltetrahydrofolate (5-MTHF), the form that actually circulates and does the work. The MTHFR gene builds that enzyme.

That single step feeds the methylation cycle, which is how the body recycles homocysteine back into methionine and supplies methyl groups to hundreds of downstream reactions. When the step runs slowly, folate accumulates in unusable forms while the usable pool stays thin.

What the variants change

Two coding variants account for most of the population-level variation.

C677T (rs1801133) substitutes a valine for an alanine and destabilises the enzyme. Carrying two copies leaves roughly a third of normal activity. Carrying one leaves an intermediate level. A1298C (rs1801131) has a milder effect on its own, and the two variants can combine in the same person.¹

The functional consequence is measurable rather than theoretical. Ulvik and colleagues inferred enzyme function directly from a population of 10,034 middle-aged adults and found the genotype tracked both folate and homocysteine status.⁷ Zappacosta and colleagues reported the same pattern in Italian adults.⁴

What the human studies found

Study	Population	Finding
Tsang et al., 2015⁵	Systematic review and meta-analysis, 40 studies, women aged 12 to 49	677TT carriers had consistently lower blood folate than CC carriers across trials and observational studies
Colson et al., 2017⁶	Meta-analysis of folic acid intervention studies	Genotype changed the folate-status response to supplementation, so the same dose did not produce the same result
Ashfield-Watt et al., 2002³	Randomised controlled trial, 126 healthy adults, 42 per genotype group	Homocysteine response to a folate-rich diet or low-dose folic acid differed by genotype
Ulvik et al., 2006⁷	10,034 adults aged 50 to 64	Functional inference confirmed reduced activity for 677T and a smaller effect for 1298C
Qin et al., 2020⁸	20,702 hypertensive adults	Serum B12 and folate interacted with MTHFR genotype on ischaemic stroke risk
van der Put et al., 1998¹	Neural-tube-defect case-control	Identified A1298C as a second common variant contributing alongside C677T

What this means for a formula

If the conversion step is slow, the sensible response is to skip it. 5-MTHF is already in the active form, so it doesn't depend on the enzyme that the variant has weakened. This is why a genotype-aware formula uses methylfolate rather than folic acid where the variant is present.

Folate doesn't work alone. The methylation cycle needs vitamin B12 to accept the methyl group, B6 for the transsulphuration branch, and riboflavin (B2) as the flavin cofactor the MTHFR enzyme itself binds. García-Minguillán and colleagues showed riboflavin status changes how strongly the MTHFR genotype affects homocysteine, which is a practical reason to supply B2 alongside folate rather than in isolation.⁹

Dose matters as much as form. Reduced activity is a matter of degree, and a heterozygote is not in the same position as someone carrying two copies.

Where the evidence is thinner. That the variant reduces enzyme activity, lowers folate status and raises homocysteine is well established across large populations. What is less settled is the size of the clinical benefit from correcting it with methylfolate specifically, versus adequate folate in any form. Klerk and colleagues found the 677TT genotype carried around 16% higher odds of coronary heart disease across 11,162 cases and 12,758 controls,¹⁰ but genotype-stratified trials of methylfolate with hard clinical endpoints remain scarce. We treat the form choice as a mechanistically sound conclusion rather than a proven outcome, and we say so on the page.

How MyGNLab uses this

MTHFR rs1801133 and rs1801131 are two of the 57 markers read from your saliva sample. Where a reduced-activity genotype is present, your formula supplies folate as 5-MTHF, at a dose scaled to how much activity the genotype predicts you've lost, with B12, B6 and riboflavin alongside it.

References

van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62(5):1044–51.
Foedinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayr J, Rasoul-Rockenschaub S, et al. Effect of MTHFR 1298A→C and MTHFR 677C→T genotypes on total homocysteine, folate, and vitamin B12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol. 2000;11(10):1918–25.
Ashfield-Watt PAL, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, et al. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr. 2002;76(1):180–6.
Zappacosta B, Graziano M, Persichilli S, Di Castelnuovo A, Mastroiacovo P, Iacoviello L. 5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms: genotype frequency and association with homocysteine and folate levels in middle-southern Italian adults. Cell Biochem Funct. 2013;32(1):1–4.
Tsang BL, Devine OJ, Cordero AM, Marchetta CM, Mulinare J, Mersereau P, et al. Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies. Am J Clin Nutr. 2015;101(6):1286–94.
Colson NJ, Naug HL, Nikbakht E, Zhang P, McCormack J. The impact of MTHFR 677 C/T genotypes on folate status markers: a meta-analysis of folic acid intervention studies. Eur J Nutr. 2017;56(1):247–60.
Ulvik A, Ueland PM, Fredriksen A, Meyer K, Vollset SE, Hoff G, et al. Functional inference of the methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms from a large-scale epidemiological study. Hum Genet. 2006;121(1):57–64.
Qin X, Spence JD, Li J, Zhang Y, Li Y, Sun N, et al. Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke. Neurology. 2020;94(11):e1126–36.
García-Minguillán CJ, Fernandez-Ballart JD, Ceruelo S, Ríos L, Bueno O, Berrocal-Zaragoza MI, et al. Riboflavin status modifies the effects of MTHFR and MTRR polymorphisms on homocysteine. Genes Nutr. 2014;9(6):435.
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023–31.

Prepared by MyGNLab from published human research. This review summarises studies conducted by third parties and is not a clinical trial run by MyGNLab. Food supplements are not a substitute for a varied, balanced diet. MyGNLab provides personalised nutrition, not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Folate status matters particularly in pregnancy: if you are pregnant, planning a pregnancy, nursing or taking medication, speak to your doctor before changing any supplement.

← All scientific reviews